Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Trial details
- Registry ID
- NCT06050122
- Drugs studied
- Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
TrialRedline tracks 4 clinical trials sponsored by Sol-Gel Technologies, Ltd.: 3 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeNCT06050122 | Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib | Completed | 2026-08-20Actual |
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)NCT03703310 | Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle | Completed | 2020-12-28Actual |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)NCT04308395 | Patidegib Topical Gel, 2% | Terminated | 2021-07-14Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCCNCT04155190 | Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle | Terminated | 2021-04-23Actual |
Names as written in the registry records.
NCT06050122 · Sol-Gel Technologies, Ltd.
Before: Estimated. After: Actual.
Before: 140 participants (planned). After: 113 participants (actual).
Before: Estimated. After: Actual.
Before: Oct 2026. After: 20 Aug 2026.
Before: Active not recruiting. After: Completed.
NCT06050122 · Sol-Gel Technologies, Ltd.
Before: Aug 2026. After: Oct 2026.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of New Surgically Eligible BCCs (nSEBs). After: Measure: Number of Participants With New Surgically Eligible Basal Cell Carcinomas (nSEBs).